Insulet Corporation (PODD)

NASDAQ
Currency in USD
324.92
+0.17(+0.05%)
Real-time Data·
PODD Scorecard
Full Analysis
11 analysts have revised their earnings upwards for the upcoming period
Trading near 52-week High
Fair Value
Day's Range
321.17326.50
52 wk Range
170.67326.50
Key Statistics
Edit
Prev. Close
324.75
Open
322.56
Day's Range
321.17-326.5
52 wk Range
170.67-326.5
Volume
282.95K
Average Vol. (3m)
920.48K
1-Year Change
73.41%
Book Value / Share
18.95
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PODD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
324.57
Downside
-0.11%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory
Show more

Insulet Corporation Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Insulet Corporation SWOT Analysis


Financial Outlook
Analyst price targets range from $234 to $266, reflecting confidence in Insulet's trajectory despite debt refinancing challenges
Leadership Transition
Recent CEO change introduces uncertainty, potentially impacting strategic direction and execution of growth initiatives
T2 Market Opportunity
Anticipated launch of Insulet's Type 2 diabetes pump could solidify first-mover advantage, despite looming competition from industry giants
Diabetes Tech Pionee
Insulet leads the tubeless insulin pump market with its Omnipod system, driving strong financial performance and international expansion
Read full SWOT analysis

Insulet Corporation Earnings Call Summary for Q1/2025

  • Q1 2025 EPS of $1.02 beat forecast by 29%; revenue grew 30% YoY to $569M, surpassing expectations
  • Gross margin improved to 71.9%, up 240 bps; stock surged 8.95% after-hours on strong results
  • FY2025 outlook: 20-23% Omnipod revenue growth; 100+ bps annual operating margin improvement targeted
  • CEO highlights leadership in automated insulin delivery; potential for growth in Type 2 diabetes market emphasized
  • Risks include supply chain disruptions, market saturation, and emerging competition in diabetes care
Last Updated: 05/08/2025, 05:33 PM
Read Full Transcript

Compare PODD to Peers and Sector

Metrics to compare
PODD
Peers
Sector
Relationship
P/E Ratio
57.0x−3.3x−0.5x
PEG Ratio
0.84−0.150.00
Price / Book
17.2x2.5x2.6x
Price / LTM Sales
10.4x3.2x3.0x
Upside (Analyst Target)
1.6%60.9%54.1%
Fair Value Upside
Unlock−3.0%8.7%Unlock

Analyst Ratings

20 Buy
3 Hold
1 Sell
Ratings:
24 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 324.57
(-0.11% Downside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
1.02 / 0.79
Revenue / Forecast
569.00M / 543.22M
EPS Revisions
Last 90 days

People Also Watch

722.69
MCK
-0.21%
371.48
APP
+2.52%
60.65
MCHP
-0.91%
311.82
UNH
+6.82%
96.60
ANET
+0.19%

FAQ

What Is the Insulet (PODD) Stock Price Today?

The Insulet stock price today is 324.92

What Stock Exchange Does Insulet Trade On?

Insulet is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Insulet?

The stock symbol for Insulet is "PODD."

What Is the Insulet Market Cap?

As of today, Insulet market cap is 22.89B.

What Is Insulet's Earnings Per Share (TTM)?

The Insulet EPS (TTM) is 5.73.

When Is the Next Insulet Earnings Date?

Insulet will release its next earnings report on Aug 07, 2025.

From a Technical Analysis Perspective, Is PODD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.